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Background: As indications for liver resection expand, objective measures to assess the risk of peri-
operative morbidity are needed. The impact of sarcopenia on patients undergoing liver resection for
colorectal liver metastasis (CRLM) was investigated.
Methods: Sarcopenia was assessed in 259 patients undergoing liver resection for CRLM by measuring
total psoas area (TPA) on computed tomography (CT). The impact of sarcopenia was assessed after
controlling for clinicopathological factors using multivariate modelling.
Results: Median patient age was 58 years and most patients (60%) were male. Forty-one (16%) patients
had sarcopenia (TPA  500 mm2/m2). Post-operatively, 60 patients had a complication for an overall
morbidity of 23%; 26 patients (10%) had a major complication (Clavien grade 3). The presence of
sarcopenia was strongly associated with an increased risk of major post-operative complications [odds
ratio (OR) 3.33; P = 0.008]. Patients with sarcopenia had longer hospital stays (6.6 vs. 5.4 days; P = 0.03)
and a higher chance of an extended intensive care unit (ICU) stay (>2 days; P = 0.004). On multivariate
analysis, sarcopenia remained independently associated with an increased risk of post-operative com-
plications (OR 3.12; P = 0.02). Sarcopenia was not significantly associated with recurrence-free [hazard
ratio (HR) = 1.07] or overall (HR = 1.05) survival (both P > 0.05).
Conclusions: Sarcopenia impacts short-, but not long-term outcomes after resection of CRLM. While
patients with sarcopenia are at an increased risk of post-operative morbidity and longer hospital stay,
long-term survival is not impacted by the presence of sarcopenia.
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Introduction
Advances in multimodality treatment of metastatic colorectal
cancer has increased survival with complete resection of colorectal
liver metastasis (CRLM) now being associated with a 5-year sur-
vival of 50–55%.1–4 With the introduction of more effective che-
motherapy regimens and widening criteria for surgical therapy,
the number of patients with CRLM eligible for surgery has also
expanded.5 Advances in operative techniques and peri-operative
care have minimised mortality with contemporary series report-
ing a mortality of less than 5%.4,6–9 Post-operative morbidity,
however, remains a concern with some studies reporting compli-
cation rates of up to 20–50%.4,7,10–13 Post-operative morbidity can
lead to prolonged hospital stays, increased need for resource
expenditure, greater medical costs and possibly even worse long-
term survival.14,15 Identification of those patients at greatest risk
for developing peri-operative complications is therefore critical.
Unfortunately, data to stratify patients with regard to the risk
of peri-operative morbidity remain ill-defined. The American
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Society of Anesthesiologist (ASA) classification, Eastern Coopera-
tive Oncology Group (ECOG) performance status and body mass
index (BMI) – among others – have been utilised with varying
degrees of success, but often fail to identify correctly those patients
at highest risk of peri-operative complications. Frailty, a measure
thought to estimate the patient’s physiologic reserves, has recently
been proposed as a more robust predictor of post-operative com-
plications.16 Assessments of frailty have been criticised, however,
for relying on scales that depend on subjective evaluations of
weakness, exhaustion and physical activity. As such, some investi-
gators have proposed using sarcopenia – depletion of muscle mass
assessed by computed tomography (CT) – as a potentially better
predictor of outcome. In general, sarcopenia is assessed by mea-
suring the surface area of skeletal muscle at the level of the third
lumbar vertebrae by measuring the total area of skeletal muscle in
this particular cross-section or by measuring the surface area of
the psoas muscle. Previous data have suggested that sarcopenia
was associated with worse outcomes among patients being treated
with chemotherapy for breast, pancreatic, prostate and renal cell
carcinoma.17–21 In addition, Englesbe et al. reported that sarcope-
nia was predictive of mortality among patients undergoing liver
transplantation.22
We herein sought to investigate the incidence of sarcopenia and
sarcopenic obesity in patients undergoing liver resection for
CRLM. Moreover, we investigated the impact of sarcopenia on
both short- and long-term outcome among patients undergoing
hepatic resection for CRLM. We hypothesise that sarcopenia and
sarcopenic obesity may be associated with increased morbidity in
patients undergoing hepatic resection for CRLM.
Methods
Patients and data collection
Between January 2000 and December 2009, 389 patients who
underwent curative intent surgery for CRLM were identified from
the Johns Hopkins Hospital liver database. Peri-operative
abdominal CT images (i.e. within 30 days of surgery) were avail-
able for re-review for 259 patients who, in turn, represent the
study cohort. Clinical and pathological data were collected includ-
ing information on demographics, primary tumour stage, extent
of metastatic disease, operative details, as well as length of inten-
sive care unit (ICU) and overall hospital stay. Data on peri-
operative mortality and morbidity were also collected. Specifically,
complications were scored using the Clavien–Dindo classification
with major complications being defined as Clavien grade  3.23
The study was approved by the Johns Hopkins Institutional
Review Board.
Image analysis
Sarcopenia was assessed by measuring the cross-sectional area of
the right and left psoas muscles (total psoas muscle area = TPA) by
three trained observers (I.K., P.P. and M.V.). TPA was measured at
the level of L3 on the first image where both vertebral spinae
were clearly visible. Measurements were performed in a semi-
automated fashion by manually outlining the borders of both
psoas muscles and setting the threshold between -30 and 110
Hounsfield Units (HU). This allowed for automatic calculation of
the total surface area of skeletal muscle in the outlined area that
excluded both vasculature and, more importantly, areas with fatty
infiltration based on the respective HU. All images were analysed
using the Ultravisual software package (Merge Emageon, Bir-
mingham, AL, USA). The measured psoas area was then norma-
lised for height, as is conventional for other body composition
measures (TPA mm/m2).24–26
Statistical analyses
Data are provided as mean and standard deviation (SD) for con-
tinuous variables and proportions for binary variables. The
impact of sarcopenia was evaluated both as a continuous and a
categorical variable. To obtain the categorical cut-off value for
sarcopenia, optimum stratification was assessed through a series
of sensitivity analyses that defined 500 mm2/m2 as the most rel-
evant cut-off value. As such, sarcopenia was defined as a TPA of
500 mm2/m2. Sarcopenic obesity was defined as the presence of
sarcopenia in patients with a BMI  30.
The impact of sarcopenia and sarcopenic obesity on postopera-
tive morbidity and mortality was examined using univariate and
multivariate analyses. Multivariate logistic regression models
included other potential predictors of outcome such as gender,
BMI and extent of liver resection. Recurrence-free and overall
survival were evaluated using the non-parametric Kaplan–Meier
method. A P-value < 0.05 was considered statistically significant.
All statistical analyses were performed using Stata 10.0 (Stata-
Corp, College station, TX, USA).
Results
Clinical, operative and sarcopenia characteristics
The clinical and pathological characteristics of the 259 patients
included in the study are outlined in Table 1. Most patients had
metastatic disease from a primary colon tumour (n = 191; 73%),
while 68 (27%) patients had a primary rectal lesion. The majority
of patients had T3/T4 primary colorectal tumors (n = 218; 84%)
and associated lymph node metastasis (n = 176; 70%). Regarding
the extent of CRLM, the median number of treated hepatic
metastasis per patient was 2 (range, 1 to 15) and the median size
of the largest lesion was 2.6 cm (range, 0.3 to 10.0 cm). At the time
of surgery, surgical treatment was resection only (n = 198; 76%) or
resection plus radiofrequency ablation (RFA) (n = 61; 24%). No
patient underwent RFA alone. A major hepatic resection (>3 seg-
ments) was undertaken in 121 patients (47%). Specifically, the
extent of hepatic resection was less than a hemihepatectomy in 7
(6%) patients, a hemihepatectomy in 84 (69%) patients and an
extended hemihepatectomy in 30 (25%) patients.
Among the 259 patients evaluated, the mean TPA was 2070 
690 mm2; after normalising for patient height, the mean TPA/m2
was 700  200 mm2/m2. Overall, 41 patients (17%) had sarcope-
nia defined as a TPA/m2  500 mm2/m2. Sarcopenia was more
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prevalent among women (32%) compared with men (5%)
(Fig. 1). While sarcopenia was observed across a wide range of
BMIs, sarcopenia was less frequently observed among obese
patients with a BMI  30 kg/m2 (Fig. 2). Of the 68 patients who
had a BMI  30 kg/m2 only 5 (2%) also had sarcopenia and
therefore were characterised as having sarcopenic obesity. Other
demographic and clinicopathological factors were similar among
sarcopenic patients vs. non-sarcopenic patients (Table 2).
Post-operative complications: influence of
sarcopenia, obesity and sarcopenic obesity
Of the 259 patients who underwent surgery for CRLM, 60 patients
developed a complication with a peri-operative morbidity rate of
23%. Morbidity after surgery was mostly associated with liver-
related complications such as post-operative bleeding (n = 6), liver
insufficiency (n = 4), liver abscess (n = 2), biloma (n = 2), sepsis
(n = 1) and portal vein thrombosis (n = 1). Other complications
included symptomatic pleural effusion requiring drainage (n = 6),
pneumonia (n = 2), and hematological (n = 3), cardiovascular
(n = 1), pulmonary (n = 2), gastrointestinal (n = 2), or other/
non-specified (n = 6). Of the 60 complications, 26 (43%) were
major in nature (Clavien grade  3). Sarcopenia was associated
with overall morbidity risk [odds ratio (OR) 2.22; P = 0.02], as
Table 1 Clinicopathological characteristics of 259 patients included
in the study
Characteristic Number (%)
Demographics
Age, mean  SD 58  12
Gender, n (%)
Male 155 (60%)
Female 104 (40%)
Anthropomorphic characteristics
BMI (kg/m2)
<30 191 (74%)
30 68 (26%)
TPA mm2/m2
500 mm2/m2 (sarcopenic) 41 (17%)
>500 mm2/m2 217 (83%)
Primary tumour characteristics
Node status, n (%)
Positive 176 (84%)
Negative 74 (16%)
Missing 9
Primary location, n (%)
Colon 191 (74%)
Rectum 68 (27%)
CRLM characteristics
Size, n (%)
<3 cm 132 (54%)
3 cm 113 (46%)
Number, n (%)
3 196 (87%)
>3 62 (13%)
Interval, n (%)
Synchronous 155 (60%)
Metachronous 104 (40%)
Hepatic surgery operative details
Extent of liver resection
Minor resection (<3 segments) 138 (53.3)
Major resection (3 segments) 121 (46.7)
RFA
Resection only 198 (76%)
Resection + RFA 61 (24%)
SD, standard deviation; BMI, body mass index; TPA, total psoas area;
CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.
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Figure 2 Scatterplot showing the distribution of total psoas area
(TPA)/m2 according to body mass index (BMI)
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well as the risk of experiencing a major complication in the peri-
operative period. Specifically, mean TPA/m2 was significantly
lower among patients who post-operatively developed Clavien
grade  3 complications compared with those patients who did
not (618  212 mm2/m2 vs. 712  197 mm2/m2, respectively; P =
0.02). Patients with sarcopenia had over a three-fold increased risk
of developing major Clavien grade  3 complications after liver
resection (Clavien grade  3 complications: non-sarcopenia 8%
vs. sarcopenia, 22%, OR 3.44; P = 0.008). On univariate analysis,
other factors, including gender, age, BMI and extent of liver resec-
tion were not associated with a risk of increased morbidity (all
P > 0.05). In a multivariate logistic regression model that
accounted for these other variables, sarcopenia remained inde-
pendently associated with a risk of major Clavien grade  3
complications (OR 3.12, 95% CI 1.14–8.49; P = 0.02) (Table 3).
Patients with sarcopenic obesity had a more pronounced risk of
Clavien grade 3 complications compared with patients who did
not have sarcopenia (sarcopenic obesity, 40% vs. non-sarcopenia
8%, P = 0.02). Only two patients died after surgery (peri-operative
mortality rate of 0.8%) and one of these had sarcopenia.
Median ICU and overall length of hospital stay was 1 (range:
0–28 days) and 5 days (range: 2–41 days), respectively. Patients
Table 2 Comparison of demographic, clinical and surgical characteristics of sarcopenic vs. non-sarcopenic patients
Characteristic Sarcopenia No sarcopenia P-value
n = 41 (15.8%) n = 218 (83.2%)
Gender
Male 8 (19.5%) 147 (67.4%) <0.001
Female 33 (80.5%) 33 (32.6%)
Mean age (SD) 59 (1.4) 58 (1.2) 0.68
BMI
<30 36 (87.8) 155 (71.1) 0.026
30 5 (12.2) 63 (28.9)
Primary tumour nodal status
Positive 28 (68.3) 148 (67.9) 0.85
Negative 11 (26.8) 63 (28.9)
No data 2 (4.9) 7 (3.3)
Timing of CRLM diagnosis
Synchronous 23 (56.1) 132 (60.6) 0.61
Metachronous 18 (43.9) 86 (39.4)
Mean size of largest CRLM, cm (SD) 2.8 (1.5) 3.1 (1.9) 0.26
Mean number of CRLM treated (SD) 2.7 (2.4) 2.8 (2.5) 0.75
Extent of liver resection
Minor 22 (53.7) 116 (53.2) 0.99
Major 19 (46.3) 102 (46.8)
RFA
Yes 8 (29.5) 53 (24.3) 0.51
No 33 (80.5) 165 (75.7)
SD, standard deviation; CRLM, colorectal liver metastasis; RFA, radiofrequency ablation.
Table 3 Results of logistic regression analysis on the correlation between post-operative complications and sarcopenia (TPA mm2/m2 500)
Univariate Multivariate
OR 95% CI P-value OR 95%CI P-value
Age (per 1 year increase) 1.00 0.97–1.04 0.85 1.00 0.97–1.04 0.79
Gender (male) 0.53 0.24–1.22 0.14 0.78 0.31–1.97 0.60
BMI (30) 1.04 0.42–2.59 0.94 1.34 0.52–3.46 0.78
Resection (major) 1.37 0.61–3.10 0.44 1.40 0.60–3.23 0.43
Sarcopenia (present) 3.33 1.36–8.09 0.008 3.12 1.14–8.49 0.02
TAP, total psoas area.
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who had sarcopenia were more likely to have a prolonged ICU stay
(i.e. > 2 days) (15%) vs. patients who did not have sarcopenia
(4%) (P = 0.004). Similarly, patients who had sarcopenia were
more likely to have a longer overall hospital stay (mean 6.6  6.1
days) vs. patients who did not have sarcopenia (mean 5.4  3.2
days) (P = 0.03). Patients with sarcopenic obesity were at an even
higher risk of a prolonged ICU (20%) and overall hospital stay
(12.6  16.1 days) (P < 0.001).
Long-term outcome: does sarcopenia have
an impact?
For the entire cohort, disease-free survival at 1-, 3- and 5-years was
65%, 28% and 26%, respectively. The median disease-free recur-
rence was 18 months. The presence of sarcopenia was not associ-
ated with the risk of recurrence. Specifically, the 5-year recurrence-
free survival was 23% vs. 27% for sarcopenic and non-sarcopenic
patients, respectively (P = 0.78) (Fig. 3a). To further explore any
potential impact of TPA on recurrence, disease-free survival was
analysed by stratifying TPA into quartiles; TPA, however, remained
not predictive of disease-free survival (Fig. 3b). Furthermore, no
difference in recurrence-free survival was noted among patients
with sarcopenic obesity when compared with the rest of the cohort
(P = 0.26). The median overall survival for the entire cohort was 46
months with a corresponding 5-year survival rate of 40%. Similar
to disease-free survival, sarcopenia was not associated with long-
term overall survival (Fig. 4). While patients with sarcopenic
obesity tended to have a shorter median survival (30 months)
compared with the rest of the cohort (46 months), this did not
reach statistical significance (P = 0.05).
Discussion
In spite of the expansion in the utilisation of liver surgery, the
mortality associated with hepatic resection has dramatically
decreased to less than 5% over the past few decades. Peri-operative
mortality is less than 5% even after extended hepatic resection,8
two-stage hepatectomy27 and resection combined with radiofre-
quency ablation.28,29 The morbidity associated with liver surgery,
however, remains problematic with a peri-operative complication
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rate of up to 50% in some series.4,7,10–13 While perhaps non-lethal,
serious complications occur in a subset of patients, which can
adversely impact patient quality of life, as well as increase hospital
utilisation and costs. There is a need therefore to identify patients
at highest risk for peri-operative complications after liver surgery
for CRLM. The present study examines a large cohort of patients
who underwent hepatic resection for CRLM to identify a possible
predictor of peri-operative morbidity.
Many patients with cancer may experience involuntary weight
loss.30,31 Weight loss may be attributable to reduced nutritional
intake (e.g. anorexia), which can be exacerbated by the side effects
of anti-cancer therapies.32 In addition, a ‘cachexia’ syndrome can
be associated with some advanced malignancies that is character-
ised by the release of endogenous transmitters, changes in inflam-
matory markers and other mediators that cause negative nitrogen
balance, fatigue and weight loss.32 Interestingly, some data have
demonstrated that body fat is lost more rapidly than lean tissue in
progressive cancer cachexia, which may be related to alterations in
circulating hormones and food intake.33 As such, some investiga-
tors have proposed using sarcopenia as a predictor of outcome.
Indeed, we found that the presence of sarcopenia was strongly
associated with an increased risk of major post-operative compli-
cations. Moreover, patients with sarcopenia had both a higher
chance of an extended ICU stay and a longer overall hospital stay.
These data have important implications as they strongly suggest
that measurements of sarcopenia, which can be easily obtained
from pre-operative cross-sectional imaging, may help identify
those patients at highest risk of peri-operative complications after
resection of CRLM.
The ability to stratify patients at risk for peri-operative compli-
cations after CRLM has several benefits. The risk prediction of
peri-operative morbidity can help provide prognostic informa-
tion to the patient, guide treatment strategies and therefore allow
more accurate comparisons of outcome among various studies/
hospitals.34 Most previous reports, however, have focused exclu-
sively on post-operative mortality, with few studies examining
factors that might be predictive of morbidity.16,34 Breitenstein et al.
proposed a pre-operative score to predict morbidity after liver
resection that included ASA grade, alanine aminotransferase
(AST), extent of liver resection and extrahepatic procedure. In the
previous study, the authors ascribed a point system to these factors
and noted that patients who had an increased score were at a
higher risk of Clavien grade  3 complications.34 This scoring
system can be criticised, however, for relying too heavily on factors
that may not be applicable to many patients undergoing liver
resection for CRLM. For example, many patients undergoing liver
resection for CRLM have a normal AST and do not undergo a
simultaneous extrahepatic procedure. As such, a scale that utilises
these two factors may not be applicable to many patients under-
going CRLM surgery. In addition, the score proposed by Breiten-
stein and colleagues relies heavily on procedure-related factors
(e.g. extent of resection and extrahepatic procedure) and pre-
dominately incorporates patient-level factors only through the use
of a ASA grade. The ASA score has, however, been criticised as a
subjective estimate of organ disease and likelihood of survival.16,35
As such, some investigators have suggested more global assess-
ments of physiological reserve such as frailty.16,36,37 In fact, Makary
et al. reported that frailty independently predicted post-operative
complications among a cohort of patients who underwent a wide
variety of elective operations at a university hospital.16 While the
use of frailty allows for a more global assessment of the patient, it
similarly can be criticised as being potentially subjective and sus-
ceptible to recall bias. Specifically, frailty scores depend on a mea-
surement of factors such as ‘exhaustion’ and ‘physical activity’,
which are assessed by questioning the patient.16 One well-
described component of frailty that can be measured more objec-
tively, however, is muscle loss/sarcopenia.38–40 While sarcopenia
can be associated with the ageing process, it has also been shown
to be accelerated with malnutrition and in chronic medical
illness.40–42 As such, sarcopenia may be an attractive objective mea-
surement of frailty and overall physiological reserve that might
help predict the risk of peri-operative morbidity.
In the present study, while peri-operative mortality was rare,
morbidity occurred in up to one-quarter of patients undergoing
surgery for CRLM. Many complications were live related includ-
ing bleeding, liver insufficiency and biloma. A full one-third of
complications were, however, non-liver related, including cardiac
and pulmonary morbidities – among others. Even more notewor-
thy was our finding that of the 60 complications noted, nearly
one-half (43%) were major in nature. While factors such as
gender, age, BMI and extent of liver resection were not associated
with morbidity, the presence of sarcopenia was strongly associated
with the risk of serious complications after surgery. Patients who
experienced a serious complication had a mean TPA mm2/m2
about 100 mm2/m2 lower than those patients who did not. This
translated into over a three-fold (OR 3.44; P = 0.008) increased
risk of developing a major Clavien grade 3 complication among
patients with sarcopenia. As such, our data strongly suggest that
the finding of muscle loss (sarcopenia) on cross-sectional imaging
may be a valuable pre-operative characteristic to stratify a
patient’s risk of peri-operative morbidity.
The impact of sarcopenia on long-term outcome remains ill
defined. Previous data have suggested that sarcopenia was associ-
ated with worse outcomes among patients being treated with che-
motherapy for a range of malignancies.17–21 In addition, Englesbe
et al. reported that sarcopenia was predictive of long-term mor-
tality among patients undergoing liver transplantation.22 Specifi-
cally, in the last study, the authors noted that when stratified into
quartiles based on psoas area, 1-year survival ranged from 50% for
the quartile with the smallest psoas area to 87% for the quartile
with the largest. Survival at 3 years among these groups was 26%
and 77%, respectively.22 In contrast, in the present study, we did
not find an association between the presence of sarcopenia and
long-term outcome. In fact, when we stratified psoas area into
quartiles, there was no discernible difference in either disease-
free or overall survival (Figs 3,4). These data emphasise that the
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impact of sarcopenia on long-term outcomes may be a function
of the underlying patient populations being studied. Whereas
the impact of sarcopenia may be more pronounced on a patient’s
ability to tolerate an acute stress such as surgery, the role that
sarcopenia has to play in long-term outcome is probably more
complicated and may involve a complex interplay between overall
general health status and the natural history of the patient’s
specific disease process.
The present study had several limitations. The study was based
on a retrospective analysis, and data on other frailty parameters
such as grip strength, walking speed or levels of exhaustion were
not captured.16 These would have allowed examination of the
impact of sarcopenia relative to other parameters of frailty. In
addition, despite being a major hepatobiliary centre, the number
of patients included in the study was somewhat limited due in
part to the incomplete availability of scans for re-review, which
required exclusion of 130 patients who had imaging performed
at outside institutions.
While mortality after hepatic resection of CRLM was rare, one-
quarter of patients experienced a peri-operative complication after
surgery and almost one-half of these were serious. Sarcopenia,
a measurement of muscle mass that can easily be obtained from
cross-sectional imaging, accurately predicted those patients at
highest risk of serious complications. In addition, the presence of
sarcopenia was associated with both a prolonged ICU and overall
hospital stay. As such, assessment of sarcopenia may provide an
easy pre-operative tool to help identify those patients at highest
risk of peri-operative morbidity after liver surgery for CRLM.
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